Samsung Bioepis Co., Ltd. and Organon & Co. announced that the US Food and Drug Administration (FDA) has designated the HADLIMA™ (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 mL, 40 mg/0.8 mL) autoinjectors and high-concentration...
Fresenius Kabi, an operating company of Fresenius, announced today that Epinephrine Injection, USP, is now available in the United States in 30 mg per 30 mL multi-dose vials. Epinephrine Injection 30 mg per 30 mL is a prescription medicine used...
Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable biosimilar to the reference product Stelara® (ustekinumab)....
Joint study by University of Shizuoka, Kobe University, and Noster Inc. uncovers a novel postbiotic pathway for obesity prevention.A new collaborative study from the University of Shizuoka, Kobe University, and Kyoto-based biotech company Noster...
Kimera Labs, Inc., the pioneer in therapeutic exosome biotechnology, is proud to announce its selection as a semifinalist in the prestigious $101 million XPRIZE Healthspan competition. This milestone recognizes Kimera's groundbreaking work in...
Rein Therapeutics a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that the RENEW Phase 2 trial of its lead asset,...
Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, has established a strategic collaboration with Trogenix, a pioneering biotech company...
PCI Pharma Services (“PCI”) – a leading global contract development and manufacturing organization (CDMO) focused on innovative biopharma therapies – has completed its acquisition of Ajinomoto Althea, Inc. (“Althea”), a US-based sterile...
Xencor, Inc.a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced positive interim results from its first-in-human study of XmAb942. A high-potency,...
Novocure announced that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) concurrently with immune checkpoint inhibitors or docetaxel who have...
Toenail fungus, medically known as onychomycosis, is more than just a cosmetic issue. It's a persistent condition that affects the appearance, health, and comfort of your feet. What begins as a small yellow or white spot under the nail can...
Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab demonstrated a highly statistically significant and clinically...
Paragonix Technologies, a leader in organ transplant technologies and services, today announced the successful completion of its hundredth case using the FDA-cleared KidneyVault™ Portable Renal Perfusion System. This milestone was achieved with...
JelloX Biotech Inc., a Taiwan-based startup at the forefront of cancer pathology, is announcing it will open a lab in the Discovery Oasis biotechnology space in Phoenix, Arizona. An expansive 120-acre development, Discovery Oasis is envisioned as...
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, announced $18M in Australian Federal Government Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate...
Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial). Glenmark's Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25...
PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel synthetic peptide called "KGF alternative- peptide (FGFR2b agonist)" which is functionally equivalent to recombinant keratinocyte...
PHC Corporation a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. announce the successful development of a new production technology(*1) for the commercialization of...
Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today confirmed it has changed its corporate name to Niagen Bioscience, Inc. (“Niagen Bioscience” or the...
UCB, a global biopharmaceutical company, announced further long-term data from the Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with moderate-to-severe plaque psoriasis (PSO). Dual inhibition...
